{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Islet+Cell+Adenoma",
    "query": {
      "condition": "Islet Cell Adenoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 91,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Islet+Cell+Adenoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:10:29.420Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05247905",
      "title": "Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Neuroendocrine Tumor",
        "Unresectable Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2023-02-16",
      "completion_date": "2033-10-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 171,
      "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Emeryville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05247905"
    },
    {
      "nct_id": "NCT01056601",
      "title": "Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Panobinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-09",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01056601"
    },
    {
      "nct_id": "NCT00325104",
      "title": "Cinacalcet to Treat Familial Primary Hyperparathyroidism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercalcemia",
        "Familial Primary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Parathyroid hormone testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Serum calcium testing",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-05-09",
      "completion_date": "2007-03-31",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325104"
    },
    {
      "nct_id": "NCT00001165",
      "title": "Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Islet Cell Adenoma",
        "Neoplasm Metastasis",
        "Zollinger Ellison Syndrome"
      ],
      "interventions": [
        {
          "name": "combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 999,
      "start_date": "1978-09",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001165"
    },
    {
      "nct_id": "NCT01229943",
      "title": "Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Pancreatic Neuroendocrine Tumor",
        "Locally Advanced Pancreatic Neuroendocrine Tumor",
        "Pancreatic Gastrinoma",
        "Pancreatic Neuroendocrine Tumor G1",
        "Pancreatic Neuroendocrine Tumor G2",
        "Pancreatic Vipoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2010-10-15",
      "completion_date": "2018-01-03",
      "has_results": true,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 388,
      "location_summary": "Mobile, Alabama • Anaheim, California • Antioch, California + 272 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01229943"
    },
    {
      "nct_id": "NCT00842348",
      "title": "Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Functioning Entero-pancreatic Endocrine Tumour"
      ],
      "interventions": [
        {
          "name": "lanreotide (Autogel formulation)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2009-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842348"
    },
    {
      "nct_id": "NCT01770405",
      "title": "Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Cyst",
        "Pancreatic Neoplasms",
        "Pancreatic Adenoma",
        "Pancreatic Cancer",
        "Pancreatic Islet Cell Tumors",
        "Lymph Node Mass",
        "Lymphadenopathy",
        "GIST"
      ],
      "interventions": [
        {
          "name": "Endoscopic ultrasound fine needle aspiration",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mauna Kea Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-09",
      "completion_date": "2016-12-21",
      "has_results": false,
      "last_update_posted_date": "2017-08-29",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Manhasset, New York • New York, New York + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01770405"
    },
    {
      "nct_id": "NCT00096083",
      "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "isolated perfusion",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delcath Systems Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2004-09",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-10-23",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096083"
    },
    {
      "nct_id": "NCT05610826",
      "title": "Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumor",
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "cytoreductive surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)",
          "type": "DRUG"
        },
        {
          "name": "Peptide receptor radionuclide therapy (PRRT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-03-07",
      "completion_date": "2024-09-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05610826"
    },
    {
      "nct_id": "NCT06663072",
      "title": "Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "177Lu-DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-12-13",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-05-22T02:10:29.420Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06663072"
    }
  ]
}